The use of mycophenolate mofetil for the treatment of autoimmune and chronic idiopathic urticaria: Experience in 19 patients - 16/04/12
Correspondence to: Nicholas A. Soter, MD, Department of Dermatology, New York University, 550 First Ave, Suite H-100, New York, NY 10016.Abstract |
Background |
There is a paucity of investigation on which to base the treatment of chronic urticaria after a patient fails maximum therapy with antihistamines. One prospective, open-label, uncontrolled study suggested that mycophenolate mofetil may be a successful second-line therapy.
Objective |
We sought to evaluate the efficacy and safety of mycophenolate mofetil in 19 patients with autoimmune and chronic idiopathic urticaria.
Methods |
In a retrospective chart review, records of patients with autoimmune and chronic idiopathic urticaria who were evaluated between 2001 and 2009 were analyzed.
Results |
Improvement in urticaria was observed in 89% of patients, specifically 91% of patients with autoimmune urticaria and 88% with chronic idiopathic urticaria. Time to initial improvement ranged from 1 to 9 weeks. In 59% of these patients, complete control of urticaria was achieved, which included 70% of patients with autoimmune urticaria and 43% with chronic idiopathic urticaria. Mean time to complete control was 14 weeks, with a range of less than 1 to 31 weeks. The dose of mycophenolate mofetil at complete control ranged from 1000 to 6000 mg divided twice daily. Mycophenolate mofetil was tapered in 7 of these 10 patients after an average of 7 weeks. Six of the 7 patients tapered then discontinued mycophenolate mofetil with remissions lasting between 2 and 16 weeks up to when the chart review ended. Mycophenolate mofetil was well tolerated with no serious infections or laboratory abnormalities. Gastrointestinal symptoms were most common.
Limitations |
This was a retrospective chart analysis. The number of patients was relatively small.
Conclusions |
Mycophenolate mofetil is a useful and well-tolerated second-line therapy for patients with autoimmune and chronic idiopathic urticaria in whom antihistamines and other therapeutic agents have failed.
Le texte complet de cet article est disponible en PDF.Key words : angioedema, autoimmune urticaria, chronic idiopathic urticaria, hives, immunomodulators, mycophenolate mofetil, treatment
Plan
| Funding sources: None. |
|
| Conflicts of interest: None declared. |
|
| Reprints not available from the authors. |
Vol 66 - N° 5
P. 767-770 - mai 2012 Retour au numéro
Article précédent
- Treatment of erosive oral lichen planus with local ultraviolet B phototherapy
- Riad Kassem, Noam Yarom, Alon Scope, Meir Babaev, Henri Trau, Felix Pavlotzky
- Skin cancer risk perceptions: A comparison across ethnicity, age, education, gender, and income
- Kesha J. Buster, Zhiying You, Mona Fouad, Craig Elmets
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?